The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommendations for the use for tofacitinib in the therapy of rheumatoid arthritis
The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommenda...
Saved in:
| Format: | Article |
|---|---|
| Language: | Russian |
| Published: |
IMA PRESS LLC
2016-10-01
|
| Series: | Научно-практическая ревматология |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2281 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Rheumatoid arthritis and cardiovascular comorbidities
by: Uğur Özkan, et al.
Published: (2023-12-01)
by: Uğur Özkan, et al.
Published: (2023-12-01)
Similar Items
-
THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01) -
Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01) -
Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis
by: Caterina Vacchi, et al.
Published: (2021-01-01) -
Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01) -
A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)